Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 5, 2010, Pages 448-455

  Aditya, N P ^a   Patankar, S ^b   Madhusudhan, B ^a   Murthy, R S R ^c   Souto, E B ^d,e  

^a KUVEMPU UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^c ISF COLLEGE OF PHARMACY   (India)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Artemether; Hepatotoxicity; Lipid nanoparticles; Malaria; Nephrotoxicity; Parasitemia; Plasmodium berghei

Indexed keywords

ANIONIC SURFACTANT; ARTEMETHER; BUFFER; CATIONIC SURFACTANT; GLYCERYLTRIMYRISTATE; LIPID; NANOPARTICLE; NONIONIC SURFACTANT; PHOSPHATE; SOYBEAN OIL; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; ENCAPSULATION; FILM; HEMOLYSIS; HISTOPATHOLOGY; HYDRATION; IN VIVO STUDY; LIVER TOXICITY; MALARIA; MOUSE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; PARASITOLOGY; PHARMACEUTICS; PLASMODIUM BERGHEI; TOXICITY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG CARRIERS; DRUG COMPOUNDING; LIPIDS; MALARIA; MICE; NANOPARTICLES; PARTICLE SIZE; PLASMODIUM BERGHEI; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953913053     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.007     Document Type: Article

References (26)

1. Akinlolu A.A., Shokunbi M.T. Neurotoxic effects of 25mg/kg/bodyweight of artemether on the histology of the trapezoid nuclei and behavioural functions in adult male Wistar rats. Acta Histochem. 2010, 112:193-198.
2. Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8:6.
3. Bhaskar K., Krishna Mohan C., Lingam M., Jagan Mohan S., Venkateswarlu V., Madhusudan Rao Y., Anbu J., Ravichandran V. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev. Ind. Pharm. 2009, 35:98-113.
4. Cavalli R., Caputo O., Marengo E., Pattarino F., Gasco M.R. The effect of components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie 1998, 53.
5. Cesar Ida C., Andrade Nogueira F.H., Antonio Pianetti G. Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection. J. Pharm. Biomed. Anal. 2008, 48:951-954.
6. Chimanuka B., Gabriels M., Detaevernier M.R., Plaizier-Vercammen J.A. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J. Pharm. Biomed. Anal. 2002, 28:13-22.
7. Colussi D., Parisot C., Legay F., Lefevre G. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur. J. Pharm. Sci. 1999, 9:9-16.
8. Dey T., Anam K., Afrin F., Ali N. Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob. Agents Chemother. 2000, 44:1739-1742.
9. Hien T.T., Davis T.M., Chuong L.V., Ilett K.F., Sinh D.X., Phu N.H., Agus C., Chiswell G.M., White N.J., Farrar J. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother. 2004, 48:4234-4239.
10. Jores K., Mehnert W., Mader K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res. 2003, 20:1274-1283.
11. Joshi M., Pathak S., Sharma S., Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject. Int. J. Pharm. 2008, 364:119-126.
12. Karbwang J., Na-Bangchang K., Congpuong K., Molunto P., Thanavibul A. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur. J. Clin. Pharmacol. 1997, 52:307-310.
13. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
14. Li Q.G., Peggins J.O., Fleckenstein L.L., Masonic K., Heiffer M.H., Brewer T.G. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 1998, 50:173-182.
15. Minetti M., Ceccarini M., Di Stasi A.M. Role of membrane thermotropic properties on hypotonic hemolysis and hypertonic cryohemolysis of human red blood cells. J. Cell. Biochem. 1984, 25:61-72.
16. Mu D., Zhang W., Chu D., Liu T., Xie Y., Fu E., Jin F. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother. Pharmacol. 2008, 61:639-645.
17. Muller R.H., Heinemann S. Fat emulsions for parenteral nutrition. I. Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr. 1992, 11:223-236.
18. Siekmann B., Westesen K. Themoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloid Surf. B: Biointerf. 1994, 3:159-175.
19. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol. 2010, 115-141.
20. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 2004, 95:627-638.
21. Wang J., Zhou H., Zheng J., Cheng J., Liu W., Ding G., Wang L., Luo P., Lu Y., Cao H., Yu S., Li B., Zhang L. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob. Agents Chemother. 2006, 50:2420-2427.
22. Wang Z., Qiu J., Guo T.B., Liu A., Wang Y., Li Y., Zhang J.Z. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:5958-5965.
23. WHO, 1986. The Use of Artemisinin and its Derivatives as Antimalarial Drugs World Health Organization. Malaria Unit Division of Control of Tropical Diseases, World Health Organization, Geneva, 1998 (WHO, WHO/MAL/98/1086).
24. White N.J., Nosten F., Looareesuwan S., Watkins W.M., Marsh K., Snow R.W., Kokwaro G., Ouma J., Hien T.T., Molyneux M.E., Taylor T.E., Newbold C.I., Ruebush T.K., Danis M., Greenwood B.M., Anderson R.M., Olliaro P. Averting a malaria disaster. Lancet 1999, 353:1965-1967.
25. Zhang X., Liu J., Qiao H., Liu H., Ni J., Zhang W., Shi Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010, 120:128.
26. Zimmermann E., Muller R.H., Mader K. Influence of different parameters on reconstitution of lyophilized SLN. Int. J. Pharm. 2000, 196:211-213.